Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

International Journal of Gynecological Cancer

Volumn 18, Issue 5, 2008, Pages 934-936

  Rauh Hain, J A ^a   Penson, R T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Ovarian clear cell adenocarcinoma; Sunitinib; VEGF

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL; SUNITINIB; TOPOTECAN; VASCULOTROPIN RECEPTOR;

ABDOMINAL HYSTERECTOMY; ADULT; ANAMNESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG INTOXICATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; PERITONEAL BIOPSY; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 51749119466     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01156.x     Document Type: Article

References (15)

1. Kennedy AW, Biscotti CV, Hart WR et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989 32 : 342 9.
2. Crozier MA, Copeland LJ, Silva EG et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989 35 : 199 203.
3. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003 202 : 97 9.
4. Zorn KK, Bonome T, Gangli L et al. Gene expression profiles of serous, endometroid and clear cell subtypes of ovarian and endometrial cancer. Clin Res 2005 11 : 6422 30.
5. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989 32 : 65 71.
6. Matsuura Y, Robertson G, Marsden DE, Kim S. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 2007 104 : 406 10.
7. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 9 : 327 37.
8. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 24 : 16 24.
9. Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 295 : 2516 24.
10. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 256 : 115 24.
11. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006 368 : 1303 4.
12. Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003 2 : 1011 21.
13. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003 101 : 3597 605.
14. Bamberger ES, Perret CW. Angiogenesis in epithelial ovarian cancer. Mol Pathol 2002 55 : 348 59.
15. Rock EP, Goodman V, Jiang JX et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007 12 : 107 13.